Salofalk (mesalazine) rectal suppositories 250 mg. №10

Description

Salofalk (mesalazine) rectal suppositories 250 mg. №10

Composition

active ingredient: mesalazine (5-aminosalicylic acid);

1 suppository contains 250 mg of mesalazine;

excipients: solid fat.

1 suppository contains 500 mg of mesalazine;

excipients: solid fat, cetyl alcohol, sodium docusate.

Dosage form

Suppositories are rectal.

Basic physical and chemical properties: suppositories from white to cream color, torpedo-shaped, with a uniform consistency and intact, smooth surface. During storage, a white coating may form on the surface as a result of recrystallization of solid fats.

Pharmacological group

The gastrointestinal tract and metabolism. Antidiarrheals, intestinal anti-inflammatory/antimicrobials. Intestinal anti-inflammatory drugs. Aminosalicylic acid and the like. Mesalazine.
ATX code A07EC02.

Pharmacological properties

It belongs to the category of agents acting on the foci of inflammation. Shows itself as an antioxidant.
Available in various application forms.
The drug Salofalk rectal suppositories begins to act from an hour and a half after administration or administration (depending on the form of application).
The forms of oral administration of the medication are protected by the membrane from the destructive effect, and therefore they fall as intended in the place of action – the small and large intestines.
Salofalk rectal suppositories is not affected by factors such as pH, other medications and food intake.
The withdrawal of the drug is carried out by the kidneys.

Indications

Treatment and prevention of gastrointestinal diseases:

• Crohn’s disease (chronic inflammatory disease with nodules)
• ulcerative colitis (chronic inflammatory disease of the colon mucosa).

Contraindications

Do not use the drug in children under 2 years of age.
Allergic reactions and high sensitivity to the active substance of the drug or auxiliary components, compounds from the salicylate group.
Salofalk is unacceptable to use in the presence of severe functional disorders of the liver and kidneys, peptic ulcer of the stomach and / or duodenum.
Patients who suffer from hemorrhagic diathesis and diseases of the blood and circulatory system should also refrain from taking the drug.

Application during pregnancy and lactation

If you follow strict indications and under the supervision of a doctor, the drug can be used up to 12 weeks of pregnancy.
It is forbidden to take Salofalk one month before the expected birth, provided that the disease does not require constant intake of the drug.
Information about taking the drug during breastfeeding is not enough, therefore it is recommended to refrain from treatment with Salofalk while breastfeeding.
If you are planning a pregnancy, you should stop taking the medication or keep the dose to a minimum.

Method of administration and dosage

When using Salofalk rectal suppositories three times a day, they are injected into the rectum in the morning, afternoon and evening before bedtime.

The desired therapeutic result can only be achieved with regular and constant use of Salofalk suppositories.

The duration of use is determined by the doctor.

Adults and elderly patients

Treatment of exacerbations of ulcerative colitis

Depending on individual clinical needs, 2 suppositories of Salofalk 250 mg or 1 suppository of Salofalk 500 mg are injected into the rectum 3 times a day (equivalent to 1500 mg of mesalazine per day).

Maintenance of remission of ulcerative colitis

1 suppository of the drug Salofalk 250 mg is injected into the rectum 3 times a day (equivalent to 750 mg of mesalazine per day).

Children

There are no sufficient data on the use of this drug in children.

Overdose

Usually, there is no overdose at a controlled dose. Overdose symptoms appear the same as the side effects.

Side effects

Salofalk is well tolerated, but sometimes (extremely rarely) patients notice pain in the joints and muscles.
Individual reactions of some people can manifest themselves in the form of allergic reactions: urticaria, spasms in the bronchi, itching, myo- and pericarditis, and fever.
In some cases, problems arise with the circulatory system, the organs of the digestive tract – abdominal pain, nausea, vomiting, inflammation in the pancreas, hepatitis and others.
Dizziness and headaches are extremely rare.
Mesalazine and drugs similar in structure to it can cause systemic lupus erythematosus syndrome.